Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
1 . (canceled)
2 . (canceled)
3 . (canceled)
4 . A method of treating or preventing a disease or condition selected from the group consisting of diabetes (Type 2), maturity-onset diabetes of the young (MODY), latent autoimmune diabetes adult (LADA), impaired glucose tolerance (IGT), impaired fasting glucose (IFG), gestational diabetes, and metabolic syndrome X, comprising administering to a mammal an effective amount of a peptide that is a GLP-1 receptor agonist and a glucagon antagonist.
5 . The method of claim 4 , wherein the peptide is selected from the group consisting of SEQ ID NOs: 6 through 32, and functionally equivalent fragments, derivatives and variants thereof.
6 . The method of claim 5 , wherein the peptide is selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 26, and SEQ ID NO: 27.
7 . The method of claim 4 , further comprising administering an α-glucosidase inhibitor with said peptide.
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . The method of claim 7 , wherein said α-glucosidase inhibitor is selected from acarbose, miglitol and voglibose.
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . (canceled)
19 . (canceled)
20 . (canceled)
21 . (canceled)